, looked at the efficacy of alpelisib, a PI3K inhibitor, with fulvestrant in HR+/HER2-, PIK3CA-mutant advanced breast cancer after patients had previously progressed on a CDK4/6 inhibitor and aromatase inhibitor [81]. Here, CYP19A1 is linked to breast cancer.